SGMOQ · Sangamo Therapeutics, Inc
$0.16
+0.00 (+0.94%)
At close · Aug 19
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt about our ability to continue to operate as a going concern. We will need substantial additional funding in the very near term to execute our operating plan and to continue to operate as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$66.70M
Shares
414.29M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$39.55M
-31.6%
FY2025
Net Income
-$122.93M
-25.5%
FY2025
Operating Margin
-306.53%
-126.6pp
FY2025
Diluted EPS
-$0.44
+10.2%
FY2025
Operating Cash Flow
-$97.21M
-44.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $34.56M | $39.55M | $57.8M | $176.23M | $111.3M | $110.7M | $118.19M | $102.43M | $84.45M | $36.57M | $19.39M | $39.54M | $45.87M | $24.13M | $21.66M | $10.32M | $20.81M | $22.19M | |
| $113.23M | $112.67M | $111.52M | $234.06M | $249.9M | $230.82M | $180.65M | $145.92M | $114.87M | $65.73M | $65.62M | $67.2M | $56.97M | $37.04M | $31.71M | $32.1M | $33.15M | $28.98M | |
| $31.65M | $34.89M | $44.73M | $61.17M | $62.68M | $63.22M | $67.1M | $61.69M | $46.74M | $27.2M | $26.33M | $19.2M | $15.68M | $13.8M | $12.14M | $14.04M | $12.59M | $12.61M | |
| — | $3.96M | $5.11M | $15.07M | $12.11M | $9.44M | $5.68M | $3.93M | $2.36M | $1.5M | $997K | $988K | $549K | $569K | $660K | $646K | $676K | $572K | |
| — | -$552K | $342K | $16.02M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $158.11M | $160.79M | $161.77M | $450.24M | $312.58M | $294.04M | $247.74M | $207.61M | $161.6M | $92.93M | $91.95M | $86.4M | $72.65M | $50.84M | $43.85M | $46.14M | $45.74M | $41.59M | |
| -$123.56M | -$121.24M | -$103.97M | -$274.01M | -$201.28M | -$183.34M | -$129.55M | -$105.18M | -$77.15M | -$56.36M | -$72.56M | -$46.86M | -$26.78M | -$26.71M | -$22.2M | -$35.82M | -$24.94M | -$19.4M | |
| — | -306.53% | -179.88% | -155.48% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -58.38% | -110.66% | -102.51% | -347.14% | -119.85% | -87.45% | |
| — | -$117.28M | -$98.86M | -$258.94M | -$189.17M | -$173.9M | -$123.87M | -$101.25M | -$74.79M | -$54.86M | -$71.56M | -$45.87M | -$26.23M | -$26.14M | -$21.54M | -$35.18M | -$24.26M | -$18.83M | |
| — | $1.3M | $1.51M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$1.75M | -$3.56M | $4.35M | — | — | — | — | — | — | — | $887K | $431K | $364K | $82K | -$66K | $71K | $81K | $547K | |
| -$124.02M | -$123.5M | -$98.11M | -$262.9M | -$191.85M | -$177.99M | -$120.78M | -$95.42M | -$68.89M | -$54.57M | -$71.67M | -$46.43M | -$26.42M | -$26.62M | — | — | — | — | |
| -$687K | -$568K | -$167K | -$5.07M | $429K | $306K | $345K | $0 | $0 | $0 | -$14K | -$5.72M | $0 | — | — | — | — | — | |
| -$123.33M | -$122.93M | -$97.94M | -$257.83M | -$192.28M | -$178.29M | -$121M | -$95.19M | -$68.33M | -$54.57M | -$71.66M | -$40.7M | -$26.42M | -$26.62M | -$22.26M | -$35.75M | -$24.85M | -$18.59M | |
| — | -310.81% | -169.45% | -146.3% | -172.76% | -161.05% | -102.37% | -92.93% | -80.91% | -149.23% | -369.58% | -102.94% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | |
| — | — | — | $0 | $0 | -$11K | -$126K | -$233K | -$555K | $0 | — | — | — | — | — | — | — | — | |
| -$120.32M | -$116.87M | -$100.88M | -$254.02M | -$196.7M | -$187.69M | -$113.13M | -$96.2M | -$69.49M | -$54.87M | -$71.64M | -$40.68M | -$26.45M | -$26.64M | -$22.25M | -$35.73M | -$24.88M | — | |
| USD/shares | — | -$0.44 | -$0.49 | -$1.48 | -$1.25 | -$1.23 | -$0.90 | -$0.85 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.44 | -$0.49 | -$1.48 | -$1.25 | -$1.23 | -$0.90 | -$0.85 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 280.19M | 201.7M | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | — |
| shares | — | 280.19M | 201.7M | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.20×
EV/EBIT
—
Peer median 18.33×
P/E (TTM)
—
Peer median 9.22×
Peer medians compare against the 298 similar-size Biotechnology companies (of 546 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $39,552,000 | $57,800,000 | $176,232,000 |